Jun. 9 at 11:44 AM
H.C. Wainwright reiterated
$ARQT Buy-
$19.
$OGN $ABBV $NVS $JNJ
H.C. Wainwright said in its note:
"The positive data from the open-label extension study reinforced the durability and favorable tolerability of Zoryve cream for the treatment of atopic dermatitis (AD), highlighting its potential as a safe and long-term treatment option for AD for patients across different ages, especially in young children.
We believe these long-term data represent another key step for driving the adoption of Zoryve cream adults and children 6 years and older, and Zoryve cream 0.05% in children aged 2-5 once approved.
The PDUFA date for Zoryve cream 0.05% is October 13. We are fully confident in a timely approval, given Arcutis' track record in adding label expansions for Zoryve. We reiterate our Buy rating and
$19 price target for Arcutis."
